Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
First Claim
Patent Images
1. A composition comprising:
- (1) synthetic nanocarriers comprising;
(a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding,(b) a B-cell antigen, and(c) immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and
(2) a pharmaceutically acceptable excipient.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising such nanocarriers. The present invention provides methods of designing, manufacturing, and using such nanocarriers and pharmaceutical compositions thereof.
372 Citations
21 Claims
-
1. A composition comprising:
-
(1) synthetic nanocarriers comprising; (a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding, (b) a B-cell antigen, and (c) immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and (2) a pharmaceutically acceptable excipient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 13, 14, 15, 16, 17, 18, 19, 20)
-
-
10. A method comprising administering to a subject an initial dose of a composition comprising:
-
(1) synthetic nanocarriers comprising; (a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding, (b) a B-cell antigen, and (c) an immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and (2) a pharmaceutically acceptable excipient; wherein the composition is in an amount effective to induce the production of anti-B-cell antigen IgG antibodies such that the peak serum concentration of anti-B-cell antigen IgG antibodies is raised to greater than 100 ng/ml in the subject after the administration. - View Dependent Claims (11, 12)
-
-
21. A method for stimulating an immune response comprising administering a composition comprising:
-
(1) synthetic nanocarriers comprising; (a) an immunofeature surface formed of an array of binding moieties, the array providing for high avidity and low affinity binding to antigen presenting cells as compared to antibody binding, (b) a B-cell antigen, and (c) an immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and (2) a pharmaceutically acceptable excipient wherein the nanocarriers comprises a plurality of moieties in an amount effective to provide a humoral response to the moieties.
-
Specification